RICHMOND, Va. / May 28, 2024 / Business Wire / Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that provides healthcare products for home-based care, self-manufactured products, proprietary product portfolio, distribution services and innovative technology, announced today that Ed Pesicka, the Company’s President and Chief Executive Officer and Alex Bruni, the Company’s Executive Vice President and Chief Financial Officer, will participate in a webcasted fireside chat at 11:00 a.m. Eastern Daylight Time on Wednesday, May 29, 2024 at Leerink Partners’ Healthcare Crossroads Conference in Austin, Texas. Owens & Minor is also hosting one-on-one meetings with investors at the conference.
Please visit the investor relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations at least 10 minutes in advance to register for the live webcast of the discussion.
About Owens & Minor
Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.
Last Trade: | US$14.41 |
Daily Change: | 0.57 4.12 |
Daily Volume: | 1,161,413 |
Market Cap: | US$1.110B |
December 02, 2024 November 04, 2024 September 10, 2024 September 09, 2024 August 02, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load